HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome
The relapse rate in antiphospholipid syndrome (APS) remains high, i.e. around 20%–21% at 5 years in thrombotic APS and 20–28% in obstetrical APS [2, 3].
Hydroxychloroquine (HCQ) appears as an additional therapy, as it possesses immunomodulatory and antithrombotic various effects [4–16].
Our group recently obtained the orphan designation of HCQ in antiphospholipid syndrome by the European Medicine Agency.
6 days ago
Antibodies that recognize the phosphatidylserine/prothrombin complex (antiphosphatidylserine/prothrombin antibodies; aPS/PT) might reveal enhanced thrombotic risk in patients with systemic lupus erythematosus. Little is known about their association with pregnancy complications in the antiphospholipid syndrome (APS).
APS is recognised as one of the main acquired prothrombotic conditions that predispose to venous thromboembolism (also
referred to as ‘acquired thrombophilia’). Nevertheless, APS is a unique prothrombotic condition since thrombotic events can also
occur in arterial vessels and in the microvasculature. Symptoms are heterogeneous and range from asymptomatic multiple, small
ischaemic episodes to catastrophic ischaemic strokes.
The incidence and prevalence of antiphospholipid syndrome are estimated at approximately 5 de novo cases per 100 000 per year
and 40–50 cases per 100 000 individuals, respectively.
Antiphospholipid antibody (aPL)-associated pregnancy complications
represent an important clinical issue because of the impact on the life of the affected women and because of their high direct and indirect costs.
The interaction between anti-Ro/SSA and anti-La/SSB autoantibodies and anti-infectious antibodies in a wide spectrum of auto-immune diseases: another angle of the autoimmune mosaic